143 related articles for article (PubMed ID: 18375912)
21. [CA 125 kinetic pattern during chemotherapy].
Carcenac G; Georges A; Bordenave L
Ann Biol Clin (Paris); 2004; 62(1):99-102. PubMed ID: 15047499
[TBL] [Abstract][Full Text] [Related]
22. The quest for ovarian cancer's Holy Grail: can CA-125 still be the chalice of early detection?
Karlan BY; McIntosh M
J Clin Oncol; 2007 Apr; 25(11):1303-4. PubMed ID: 17416848
[No Abstract] [Full Text] [Related]
23. Statistical interpretation of CA125 and Bcl-2 in serum of patients with late stage ovarian cancer.
Camlica H; Duranyildiz D; Tas F; Yasasever V
Am J Clin Oncol; 2008 Dec; 31(6):585-8. PubMed ID: 19060592
[TBL] [Abstract][Full Text] [Related]
24. Total procollagen type 1 amino-terminal propeptide (total P1NP) as a bone metastasis marker in gynecological carcinomas.
Oremek G; Sauer-Eppel H; Klepzig M
Anticancer Res; 2007; 27(4A):1961-2. PubMed ID: 17649805
[TBL] [Abstract][Full Text] [Related]
25. [CA 125 in epithelial ovarian cancer].
Mogensen O
Ugeskr Laeger; 1998 May; 160(22):3236. PubMed ID: 9621807
[No Abstract] [Full Text] [Related]
26. Coexistence of struma ovarii with marked ascites and elevated CA-125 levels: case report and literature review.
Mui MP; Tam KF; Tam FK; Ngan HY
Arch Gynecol Obstet; 2009 May; 279(5):753-7. PubMed ID: 18807056
[TBL] [Abstract][Full Text] [Related]
27. Ovarian cancer screening. American College of Radiology. ACR Appropriateness Criteria.
Böhm-Vélez M; Mendelson E; Bree R; Finberg H; Fishman EK; Hricak H; Laing F; Sartoris D; Thurmond A; Goldstein S
Radiology; 2000 Jun; 215 Suppl():861-71. PubMed ID: 11037511
[No Abstract] [Full Text] [Related]
28. Monitoring ovarian cancer: CA125 trial stirs controversy.
Chitale R
J Natl Cancer Inst; 2009 Sep; 101(18):1233-5. PubMed ID: 19738165
[No Abstract] [Full Text] [Related]
29. Re: "clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation".
Menczer J
Gynecol Oncol; 2005 Mar; 96(3):906-7; author reply 907. PubMed ID: 15721450
[No Abstract] [Full Text] [Related]
30. [Psammoma bodies in cytological vaginal smears in metastatic ovarian carcinoma].
Erz W; Stoll P; Schrage R
Geburtshilfe Frauenheilkd; 1995 Apr; 55(4):229-30. PubMed ID: 7789713
[TBL] [Abstract][Full Text] [Related]
31. Circulating calprotectin in ovarian carcinomas and borderline tumors of the ovary.
Ødegaard E; Davidson B; Elgaaen BV; Fagerhol MK; Engh V; Onsrud M; Staff AC
Am J Obstet Gynecol; 2008 Apr; 198(4):418.e1-7. PubMed ID: 18241816
[TBL] [Abstract][Full Text] [Related]
32. Relapse and survival in early-stage ovarian cancer.
Lenhard SM; Bufe A; Kümper C; Stieber P; Mayr D; Hertlein L; Kirschenhofer A; Friese K; Burges A
Arch Gynecol Obstet; 2009 Jul; 280(1):71-7. PubMed ID: 19093129
[TBL] [Abstract][Full Text] [Related]
33. Biomarkers for the early detection of cancer: an inflammatory concept.
Roy HK; Khandekar JD
Arch Intern Med; 2007 Sep; 167(17):1822-4. PubMed ID: 17893302
[No Abstract] [Full Text] [Related]
34. Prognostic significance of CA-125 in the management of patients with recurrent epithelial ovarian carcinoma selected for secondary cytoreduction.
Mahner S; Woelber L; Jung S; Eulenburg CZ; Ihnen M; Schwarz J; Sehouli J; Jaenicke F
Anticancer Res; 2009 Jul; 29(7):2817-21. PubMed ID: 19596967
[TBL] [Abstract][Full Text] [Related]
35. Preoperative serum CA125 in surgical stage 1 epithelial ovarian cancer.
Obermair A
Gynecol Oncol; 2007 Nov; 107(2):357-8. PubMed ID: 17706272
[No Abstract] [Full Text] [Related]
36. Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors.
Begum FD; Høgdall E; Kjaer SK; Blaakaer J; Christensen IJ; Christensen L; Høgdall C
Gynecol Oncol; 2009 May; 113(2):221-7. PubMed ID: 19261323
[TBL] [Abstract][Full Text] [Related]
37. Tumour biomarkers in heart failure: is there a role for CA-125?
Yilmaz MB; Nikolaou M; Cohen Solal A
Eur J Heart Fail; 2011 Jun; 13(6):579-83. PubMed ID: 21525015
[TBL] [Abstract][Full Text] [Related]
38. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform.
Resnick KE; Alder H; Hagan JP; Richardson DL; Croce CM; Cohn DE
Gynecol Oncol; 2009 Jan; 112(1):55-9. PubMed ID: 18954897
[TBL] [Abstract][Full Text] [Related]
39. [Screening for ovarian cancers: what is the role for marker levels?].
Dargent D
Gynecol Obstet Fertil; 2000 Nov; 28(11):855-9. PubMed ID: 11127045
[No Abstract] [Full Text] [Related]
40. Familial ovarian cancer screening.
Stirling D; Porteous ME; Evans DG; Pichert G; Steel M
J Clin Oncol; 2006 Feb; 24(6):e11. PubMed ID: 16484689
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
